by A dual chamber prefilled syringe consists of two barrels, each containing a different formulation or substance that must remain separated until injection. They provide an effective means of delivering reconstituted products as the mixing of two chambers is only done at the point of injection by pushing one or both plungers. Dual chamber prefilled syringes find applications in delivery of lyophilized proteins, antibody drug conjugates, and freeze-dried products that require reconstitution prior to use. They offer advantages such as improved stability of drugs, ensured accuracy of mixing ratios, ease of administration to patients, and reduced risk of microbial contamination. Growing prevalence of chronic diseases worldwide has increased the demand for biologics which in turn is fueling the demand for dual chamber prefilled syringes for effective delivery of such drugs.
The Global Dual Chamber Prefilled Syringes Market is estimated to be valued at US$ 171.8 Mn in 2024 and is expected to exhibit a CAGR of 7.3% over the forecast period 2024 To 2031.
Key Takeaways
The key opportunities in the Dual Chamber Prefilled Syringes Market Size include rise in clinical pipeline drugs requiring reconstitution and growing demand for home healthcare devices. In addition, advancement in materials to develop prefilled syringes for highly viscous drugs is expected to boost the adoption of dual chamber prefilled syringes.
Key players operating in the Dual Chamber Prefilled Syringes are Pfizer Inc., NIPRO PHARMA CORPORATION, Gerresheimer AG, Vetter Pharma, Credence MedSystems, Inc., ARTE Corporation, BD, MAEDA INDUSTRY Co., Ltd., Bayer, Stevanato Group. The market players are involved in new product launches and enhancing their production capacities to meet the growing demand from pharmaceutical companies.
Technological advancements such as introduction of dual chamber prefilled syringes with intuitive mixing mechanisms, automated manufacturing equipment with real-time monitoring ability, and development of barrier coatings to enhance stability of drugs are expected to drive the dual chamber prefilled syringes market growth.
Market Drivers
Growing geriatric population susceptible to chronic diseases such as diabetes, cancer and auto-immune disorders is a major market driver. As per the United Nations data, there were 703 million people aged 65 years and above globally in 2019 which is expected to reach 1.5 billion by 2050. Further, surge in adoption of biologics over conventional drugs for treatment is also fueling the demand for dual chamber prefilled syringes as biologics often require reconstitution prior to use.
Current challenges in Dual Chamber Prefilled Syringes Market
The Dual Chamber Prefilled Syringes Market Size has experienced tremendous growth in recent years. However, it still faces some challenges.
One challenge is complexity in manufacturing. Dual chamber prefilled syringes have separate chambers to store two different drugs or formulations that need to be mixed just before injection. This level of complexity makes the manufacturing process more difficult and expensive compared to traditional prefilled syringes.
Another challenge is maintaining drug stability over the shelf life of the product. Since the drugs are stored separately in a dual chamber system, there are greater risks of chemical degradation or interaction between the drugs over time before use. Manufacturers need to conduct extensive stability testing to ensure the drugs remain potent and safe to use throughout the labeled expiry period.
SWOT Analysis
Strength: Separate chambers enable storage of drugs that need to be mixed just before injection. This offers formulation benefits.
Weakness: More complex design and manufacturing process increases costs compared to traditional prefilled syringes.
Opportunity: Growing demand for combination therapies and biologics driving interest in dual chamber syringe technology.
Threats: Require extensive validation to ensure drug stability over shelf life which increases development timelines and costs.
Geographical regions
North America currently accounts for the largest share of the dual chamber prefilled syringes market, in terms of value. This is attributed to the rising incidence of chronic diseases like cancer and high adoption of self-administrable drug delivery devices. Additionally, presence of major pharmaceutical companies involved in development of novel combination therapies boosts regional market growth.
Asia Pacific is poised to be the fastest growing region during the forecast period. This is due to increasing healthcare expenditure, large patient population, and growing awareness about benefits of self-injection devices in countries like China, India and Japan. Emerging biotech industries in these countries are also driving research on combination therapies suitable for dual chamber prefilled syringes.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
